Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator
Open Access
- 1 January 2020
- journal article
- research article
- Published by Yonsei University College of Medicine in Yonsei Medical Journal
- Vol. 61 (8) , 712-719
Abstract
Kwon HC, et al. Yonsei Med J. 2020 Aug;61(8):712-719. https://doi.org/10.3349/ymj.2020.61.8.712Keywords
Funding Information
- Korea Health Industry Development Institute (HI14C1324)
This publication has 16 references indexed in Scilit:
- Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Korea: A Narrative ReviewYonsei Medical Journal, 2019
- Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trialmAbs, 2018
- Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled studyThe Lancet Haematology, 2017
- CT-P10 (Truxima™): A Rituximab BiosimilarBioDrugs, 2017
- EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitisAnnals of the Rheumatic Diseases, 2016
- 2012 Revised International Chapel Hill Consensus Conference Nomenclature of VasculitidesArthritis & Rheumatism, 2012
- Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten‐year experience at a single centerArthritis & Rheumatism, 2012
- Rituximab versus Cyclophosphamide in ANCA-Associated Renal VasculitisNew England Journal of Medicine, 2010
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisNew England Journal of Medicine, 2010
- Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studiesAnnals of the Rheumatic Diseases, 2007